News of Note—Abzena invests in California, Catalent in China

Cancer in newspaper clipping

> Abzena is investing $20 million to add two manufacturing suites at the 500 liter and 2000 liter scale, at its manufacturing facility in San Diego, California. Release

> Catalent Pharma Solutions will invest $2.5 million in a second clinical supply facility in Shanghai, China, which will employ about 100 people when it opens in early 2019. Release

> The FDA is instituting new protocols to gather data from sterile injectable manufacturers in an effort to raise quality and avoid shortages. Release


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

> Dave Tudor, Ph.D., previously head of manufacturing strategy for GlaxoSmithKline, has been appointed managing director of the Medicines Manufacturing Innovation Centre, a collaboration among GSK, AstraZeneca, CPI and the University of Strathclyde in Scotland. Release

> For the first time in 30 years the U.S. will have a domestic supply of Iodine-131 (I-131), a critical radioisotope for diagnosing and treating thyroid cancer and hyperthyroidism. The supply is being produced by the University of Missouri. Release

Suggested Articles

Having only just completed an expansion in Illinois, PCI Pharma Services will now expand its solid dose facility in Wales in the U.K.

The FDA has come down on a small U.S. drugmaker for taking a skin medication to market even though there were out-of-spec test results at release.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.